GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI
12.5.2026 03:00:00 CEST | Business Wire | Press Release
GIGABYTE Technology, a global leader in high-performance computing, is taking its most comprehensive end-to-end portfolio for AI infrastructure to COMPUTEX 2026 under the theme "Future Landing." As AI transitions from training into large-scale inference and real-world operation, GIGABYTE addresses the industry's most pressing challenge: not whether AI can be built, but how quickly and reliably it can be deployed, operated, and sustained at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299592/en/
GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI
At COMPUTEX, GIGABYTE organizes its showcase around three states that define the lifecycle of production AI infrastructure.
- Ready: integrated systems that have been fully built, simulated, validated, and prepared for deployment.
- Deployable: modular clusters engineered for rapid implementation across diverse environments.
- Happening: AI systems actively running, delivering outcomes, and sustaining operations in the real world.
“AI-ready” in the Infrastructure Era
AI workloads now span centralized training clusters, distributed inference deployments, and physical environments where machines must act on real-time data. Each stage demands infrastructure that functions as a coordinated system, not a collection of individual components. Deployment speed, operational stability, and long-term efficiency have become the defining measures of AI infrastructure maturity.
GIGABYTE anchors this capability in GAIFA (GIGABYTE AI Factory Accelerator), a purpose-built AI factory in Taiwan that integrates latest compute platforms, high-speed networking, and GIGABYTE's own management software into a fully validated, end-to-end architecture. More than a testing environment, GAIFA represents how an AI factory can be built, validated, and prepared for deployment at scale.
Built for Deployment
Deploying AI infrastructure quickly is becoming a critical differentiator. It requires systems designed to be built, delivered, and operational from day one.
GIGABYTE addresses this with a modular, prefabricated infrastructure approach that integrates compute, cooling, and power into deployable units. These systems are designed to shorten deployment timelines while enabling organizations to scale AI capacity without the delays of traditional data center construction.
GIGABYTE's portfolio supports AI workloads across every stage of operation and is unified through GPM (GIGABYTE POD Manager). This software platform provides visibility and control across AI data center infrastructure, enabling operators to manage resources, optimize workloads, and maintain stability as systems scale.
AI Happening: From Physical Automation to Clinical Decision Support
The most compelling measure of AI infrastructure is what it enables in the real world. GIGABYTE demonstrates this across physical AI automation and healthcare.
In physical AI automation, GIGABYTE presents a real-to-sim-to-real pipeline showing how AI models move from simulation into robotic systems performing precise tasks in real time—a working example of Physical AI in operation, not a research demonstration.
In healthcare, GIGABYTE brings AI inference to the point of care, supporting applications including real-time polyp detection, bone marrow analysis, and pulmonary imaging. All inference runs locally, ensuring data privacy and faster clinical decision-making.
Across both domains, AI is moving closer to where data is generated and decisions are made, delivering faster response, improved accuracy, and more efficient workflows.
GIGABYTE invites all visitors around the world to engage with AI infrastructure that has moved beyond the planning stage. With "Future Landing," GIGABYTE is not only presenting a vision of what AI could become, but also demonstrating what it looks like when ready, deployed, and already operating in the real world. In addition of its 1st floor exhibit, GIGABYTE will also present a dedicated exhibit on the 4th floor, featuring AI solutions for edge and end-user applications, including systems from its AI TOP series, demonstrating how its AI capabilities extend from infrastructure to deskside scenarios.
GIGABYTE@COMPUTEX 2026
https://www.gigabyte.com/Events/Computex
June 2-5, 2026
TaiNEX, Hall 1
Enterprise(1F K0802) Consumer(4F M0520)
View source version on businesswire.com: https://www.businesswire.com/news/home/20260505299592/en/
Contacts
Media Contact: brand@gigabyte.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom